Abstract
RATIONALE: Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor is associated with delayed wound healing. Sugar, a traditional remedy for wound healing, has shown significant efficacy in accelerating recovery. Here, we developed a new strategy for managing bevacizumab-associated delayed wound healing with the topical application of sugar. PATIENT CONCERNS: A 42-year-old female with non-small cell lung cancer and brain metastases who underwent emergency surgical treatment for acute appendicitis while on bevacizumab developed delayed wound healing postoperatively. DIAGNOSES: At 50 days postoperatively, the wound was still approximately 2 cm, indicating bevacizumab-associated delayed wound healing. INTERVENTIONS: The patient had enlarged brain metastases and increased edema due to discontinuation of bevacizumab. Bevacizumab was reintroduced without complete wound healing. Concurrently, topical sugar was applied following routine wound disinfection. OUTCOMES: The wound completely healed 21 days after initiating sugar therapy, coinciding with ongoing bevacizumab treatment. LESSONS: The patient's wound healed completely with the application of topical sugar, even in the context of ongoing bevacizumab therapy, highlighting the efficacy of sugar in managing bevacizumab-induced delayed wound healing.